Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

ault.asp.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... There’s a ... Minerva is the first commercially available new FDA approved system in the last ... rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient ...
(Date:8/30/2015)... England , August 31, 2015 ...   einer Frau   für chirurgische   Behandlung     ... von 7-90   werden für eine   verheerende ... 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen in ... Astellas gab heute bekannt, dass  Action on Fistula ...
(Date:8/28/2015)... 28, 2015 According to a ... Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human ... Trials), End User - Global Forecast to 2020", published ... reach USD 3,731.03 Million by 2020 from USD 2,150.48 ... between 2015 and 2020. Browse 74 ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... has organized and will present a session on chemical spectroscopic imaging at JASIS ... and exposition is Asia’s largest analytical and scientific instruments show which will be ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... PRINCETON, N.J., Feb. 5 Celator Pharmaceuticals today,announced ... scheduled,to present on the company,s business operations and ... Organization (BIO) CEO,and Investor Conference on Tuesday, February ... New York City., About Celator, Celator ...
... (OTC Bulletin Board: NILT), announced today that Peter M. ... & Investor Conference,at the Waldorf-Astoria Hotel in New York ... Mr. Strumph will provide an overview of Nile and ... will be webcast live and can be accessed by ...
... Collections to Begin at ProHEALTH Facility by End of ... Inc. (Amex: NBS ),which is pioneering the pre-disease ... future medical need, today announced,receipt of a provisional license ... stem cells from the New York State,Department of Health ...
Cached Biology Technology:Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference 2NeoStem Announces NY State License for Adult Stem Cell Collection 2NeoStem Announces NY State License for Adult Stem Cell Collection 3
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... fat capsules, often added to beauty products. According ... active ingredients deep into the skin and release the ... structure by rejuvenating and smoothing the skin. ... liposomes are not capable of transporting themselves deep into ...
... Organic rice studies have moved to the front burner ... AgriLife Research scientists. Two studies, led by Dr. Fugen ... Station, Corpus Christi, Arkansas, Alabama and South Carolina will ... environmentally friendly way. The research projects are funded by the ...
... Raman spectroscopy has enabled incredible advances in ... for tissue classification and disease recognition, although there ... in a clinical setting. Scientists have now demonstrated ... door to wider biomedical and clinical applications such ...
Cached Biology News:Don't trust liposomes in your beauty products 2Organic rice research moves to front burner in Texas 2Breakthrough study opens door to broader biomedical applications for Raman spectroscopy 2
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... is designed for easy transformation of the ... for successful transformation simply by mixing a ... cultured yeast cells. No complicated steps, such ... The kit is particularly well suited for ...
... enable rapid analytical to medium scale affinity ... appropriate vectors. Sufficient reagents are provided for ... protein under native or denaturing conditions. Crude ... specifically retains STag fusion proteins. After unbound ...
Request Info...
Biology Products: